{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,3,17]],"date-time":"2025-03-17T03:10:34Z","timestamp":1742181034742,"version":"3.38.0"},"reference-count":39,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2024,3,1]],"date-time":"2024-03-01T00:00:00Z","timestamp":1709251200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,3,1]],"date-time":"2024-03-01T00:00:00Z","timestamp":1709251200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,12,30]],"date-time":"2023-12-30T00:00:00Z","timestamp":1703894400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100019229","name":"ViewRay Inc","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100019229","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["ctro.science","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical and Translational Radiation Oncology"],"published-print":{"date-parts":[[2024,3]]},"DOI":"10.1016\/j.ctro.2023.100719","type":"journal-article","created":{"date-parts":[[2024,1,5]],"date-time":"2024-01-05T09:05:41Z","timestamp":1704445541000},"page":"100719","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["Multi-institutional experience of MR-guided stereotactic body radiation therapy for adrenal gland metastases"],"prefix":"10.1016","volume":"45","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-8483-105X","authenticated-orcid":false,"given":"Matthew","family":"Mills","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rupesh","family":"Kotecha","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1027-8981","authenticated-orcid":false,"given":"Roberto","family":"Herrera","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tugce","family":"Kutuk","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Matthew","family":"Fahey","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Evan","family":"Wuthrick","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"G. Daniel","family":"Grass","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sarah","family":"Hoffe","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1901-0933","authenticated-orcid":false,"given":"Jessica","family":"Frakes","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michael D.","family":"Chuong","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Stephen A.","family":"Rosenberg","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.ctro.2023.100719_b0005","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1046\/j.0300-0664.2001.01435.x","article-title":"Metastatic tumours of the adrenal glands: a 30-year experience in a teaching hospital","volume":"56","author":"Lam","year":"2002","journal-title":"Clin Endocrinol (Oxf)"},{"key":"10.1016\/j.ctro.2023.100719_b0010","doi-asserted-by":"crossref","first-page":"2699","DOI":"10.21873\/anticanres.13395","article-title":"Metastatic carcinomas of the adrenal glands: from diagnosis to treatment","volume":"39","author":"Spartalis","year":"2019","journal-title":"Anticancer Res"},{"key":"10.1016\/j.ctro.2023.100719_b0015","doi-asserted-by":"crossref","first-page":"1558","DOI":"10.1200\/JCO.19.00201","article-title":"Local consolidative therapy vs. maintenance therapy or observation for patients with oligometastatic non-small-cell lung cancer: long-term results of a multi-institutional, phase II, randomized study","volume":"37","author":"Gomez","year":"2019","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ctro.2023.100719_b0020","doi-asserted-by":"crossref","first-page":"2830","DOI":"10.1200\/JCO.20.00818","article-title":"Stereotactic ablative radiotherapy for the comprehensive treatment of oligometastatic cancers: long-term results of the SABR-COMET phase II randomized trial","volume":"38","author":"Palma","year":"2020","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ctro.2023.100719_b0025","doi-asserted-by":"crossref","first-page":"3824","DOI":"10.1200\/JCO.2014.56.7412","article-title":"Phase II trial of stereotactic body radiation therapy combined with erlotinib for patients with limited but progressive metastatic non-small-cell lung cancer","volume":"32","author":"Iyengar","year":"2014","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ctro.2023.100719_b0030","doi-asserted-by":"crossref","first-page":"1732","DOI":"10.1016\/S1470-2045(21)00528-3","article-title":"Definitive radiotherapy in lieu of systemic therapy for oligometastatic renal cell carcinoma: a single-arm, single-centre, feasibility, phase 2 trial","volume":"22","author":"Tang","year":"2021","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.ctro.2023.100719_b0035","doi-asserted-by":"crossref","DOI":"10.1016\/j.radonc.2023.109681","article-title":"EGFR-TKIs plus stereotactic body radiation therapy (SBRT) for stage IV non-small cell lung cancer (NSCLC): A prospective, multicenter, randomized, controlled phase II study","volume":"184","author":"Peng","year":"2023","journal-title":"Radiother Oncol"},{"key":"10.1016\/j.ctro.2023.100719_b0040","doi-asserted-by":"crossref","first-page":"585","DOI":"10.1007\/s10585-020-10052-0","article-title":"Adrenal SBRT: a multi-institutional review of treatment outcomes and toxicity","volume":"37","author":"Helis","year":"2020","journal-title":"Clin Exp Metastasis"},{"key":"10.1016\/j.ctro.2023.100719_b0045","doi-asserted-by":"crossref","first-page":"536","DOI":"10.1186\/s12885-020-07030-w","article-title":"Single-institutional outcome-analysis of low-dose stereotactic body radiation therapy (SBRT) of adrenal gland metastases","volume":"20","author":"Voglhuber","year":"2020","journal-title":"BMC Cancer"},{"key":"10.1016\/j.ctro.2023.100719_b0050","doi-asserted-by":"crossref","first-page":"621","DOI":"10.1016\/j.adro.2018.05.006","article-title":"Stereotactic body radiation therapy for adrenal gland metastases: Outcomes and toxicity","volume":"3","author":"Toesca","year":"2018","journal-title":"Adv Radiat Oncol"},{"key":"10.1016\/j.ctro.2023.100719_b0055","doi-asserted-by":"crossref","first-page":"945","DOI":"10.1097\/COC.0000000000000610","article-title":"The prognostic role of pretreatment neutrophil to lymphocyte ratio (NLR) in malignant adrenal lesions treated with stereotactic body radiation therapy (SBRT)","volume":"42","author":"Mills","year":"2019","journal-title":"Am J Clin Oncol"},{"key":"10.1016\/j.ctro.2023.100719_b0060","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1097\/COC.0000000000000634","article-title":"Novel dose escalation approaches for stereotactic body radiotherapy to adrenal oligometastases: a single-institution experience","volume":"43","author":"Figura","year":"2020","journal-title":"Am J Clin Oncol"},{"key":"10.1016\/j.ctro.2023.100719_b0065","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1016\/j.ijrobp.2020.01.017","article-title":"Stereotactic body radiation therapy of adrenal metastases: A pooled meta-analysis and systematic review of 39 studies with 1006 patients","volume":"107","author":"Chen","year":"2020","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.ctro.2023.100719_b0070","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1007\/s00117-020-00781-4","article-title":"MR-guided radiotherapy of moving targets","volume":"61","author":"Spindeldreier","year":"2021","journal-title":"Radiologe"},{"key":"10.1016\/j.ctro.2023.100719_b0075","doi-asserted-by":"crossref","unstructured":"van Sornsen de Koste JR, Palacios MA, Chen H, Schneiders FL, Bruynzeel AME, Slotman BJ, et al. Changes in gastric anatomy after delivery of breath-hold MR-guided SABR for adrenal metastases. Radiother Oncol 2020;152:26-9.","DOI":"10.1016\/j.radonc.2020.07.045"},{"key":"10.1016\/j.ctro.2023.100719_b0080","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1016\/j.radonc.2021.11.024","article-title":"CT-guided versus MR-guided radiotherapy: Impact on gastrointestinal sparing in adrenal stereotactic body radiotherapy","volume":"166","author":"Rodriguez","year":"2022","journal-title":"Radiother Oncol"},{"key":"10.1016\/j.ctro.2023.100719_b0085","doi-asserted-by":"crossref","DOI":"10.3390\/jcm12010291","article-title":"Stereotactic MR-guided radiotherapy for adrenal gland metastases: first clinical results","volume":"12","author":"Michalet","year":"2022","journal-title":"J Clin Med"},{"key":"10.1016\/j.ctro.2023.100719_b0090","doi-asserted-by":"crossref","first-page":"e18","DOI":"10.1016\/S1470-2045(19)30718-1","article-title":"Characterisation and classification of oligometastatic disease: a European Society for Radiotherapy and Oncology and European Organisation for Research and Treatment of Cancer consensus recommendation","volume":"21","author":"Guckenberger","year":"2020","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.ctro.2023.100719_b0095","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1016\/j.adro.2018.08.005","article-title":"A multi-institutional experience of MR-guided liver stereotactic body radiation therapy","volume":"4","author":"Rosenberg","year":"2019","journal-title":"Adv Radiat Oncol"},{"key":"10.1016\/j.ctro.2023.100719_b0100","doi-asserted-by":"crossref","first-page":"e45","DOI":"10.1016\/j.prro.2022.07.001","article-title":"A practical workflow for magnetic resonance-guided stereotactic body radiation therapy to the pancreas","volume":"13","author":"Sim","year":"2023","journal-title":"Pract Radiat Oncol"},{"key":"10.1016\/j.ctro.2023.100719_b0105","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2023.1061854","article-title":"Adaptive hypofractionted and stereotactic body radiotherapy for lung tumors with real-time MRI guidance","volume":"13","author":"Bryant","year":"2023","journal-title":"Front Oncol"},{"issue":"Suppl 1","key":"10.1016\/j.ctro.2023.100719_b0110","doi-asserted-by":"crossref","first-page":"122S","DOI":"10.2967\/jnumed.108.057307","article-title":"From RECIST to PERCIST: evolving considerations for PET response criteria in solid tumors","volume":"50","author":"Wahl","year":"2009","journal-title":"J Nucl Med"},{"key":"10.1016\/j.ctro.2023.100719_b0115","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1016\/j.ejca.2008.10.026","article-title":"New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1)","volume":"45","author":"Eisenhauer","year":"2009","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.ctro.2023.100719_b0120","doi-asserted-by":"crossref","first-page":"7836","DOI":"10.1038\/s41598-020-64770-2","article-title":"Clinical efficacy of Stereotactic Body Radiation Therapy (SBRT) for adrenal gland metastases: A multi-center retrospective study from China","volume":"10","author":"Zhao","year":"2020","journal-title":"Sci Rep"},{"key":"10.1016\/j.ctro.2023.100719_b0125","doi-asserted-by":"crossref","first-page":"511","DOI":"10.1007\/s10585-021-10124-9","article-title":"Stereotactic body radiation therapy for adrenal gland metastases: outcome and predictive factors from a multicenter analysis","volume":"38","author":"Franzese","year":"2021","journal-title":"Clin Exp Metastasis"},{"key":"10.1016\/j.ctro.2023.100719_b0130","doi-asserted-by":"crossref","first-page":"e195","DOI":"10.1016\/j.prro.2016.09.005","article-title":"Stereotactic ablative radiotherapy for adrenal gland metastases: Factors influencing outcomes, patterns of failure, and dosimetric thresholds for toxicity","volume":"7","author":"Chance","year":"2017","journal-title":"Pract Radiat Oncol"},{"key":"10.1016\/j.ctro.2023.100719_b0135","doi-asserted-by":"crossref","first-page":"509","DOI":"10.1097\/COC.0b013e3182569189","article-title":"Stereotactic body radiotherapy in the treatment of adrenal metastases","volume":"36","author":"Ahmed","year":"2013","journal-title":"Am J Clin Oncol"},{"key":"10.1016\/j.ctro.2023.100719_b0140","doi-asserted-by":"crossref","first-page":"618","DOI":"10.3109\/0284186X.2011.652738","article-title":"Long-term local control achieved after hypofractionated stereotactic body radiotherapy for adrenal gland metastases: a retrospective analysis of 34 patients","volume":"51","author":"Scorsetti","year":"2012","journal-title":"Acta Oncol"},{"key":"10.1016\/j.ctro.2023.100719_b0145","doi-asserted-by":"crossref","first-page":"426","DOI":"10.1016\/j.ijrobp.2018.06.002","article-title":"Role of daily plan adaptation in MR-guided stereotactic ablative radiation therapy for adrenal metastases","volume":"102","author":"Palacios","year":"2018","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.ctro.2023.100719_b0150","doi-asserted-by":"crossref","DOI":"10.1016\/j.radonc.2023.109749","article-title":"Tumor volume changes during stereotactic ablative radiotherapy for adrenal gland metastases under MRI guidance","volume":"186","author":"Giraud","year":"2023","journal-title":"Radiother Oncol"},{"key":"10.1016\/j.ctro.2023.100719_b0155","doi-asserted-by":"crossref","first-page":"S33","DOI":"10.1016\/S0167-8140(19)30492-X","article-title":"Clinical outcomes of stereotactic MR-guided adaptive radiation therapy for adrenal oligometastases","volume":"133","author":"Cobussen","year":"2019","journal-title":"Radiother Oncol"},{"key":"10.1016\/j.ctro.2023.100719_b0160","doi-asserted-by":"crossref","first-page":"1399","DOI":"10.1016\/j.ijrobp.2016.03.050","article-title":"Radiosensitivity differences between liver metastases based on primary histology suggest implications for clinical outcomes after stereotactic body radiation therapy","volume":"95","author":"Ahmed","year":"2016","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.ctro.2023.100719_b0165","doi-asserted-by":"crossref","first-page":"1121","DOI":"10.1016\/j.jtho.2018.04.027","article-title":"Radiosensitivity of lung metastases by primary histology and implications for stereotactic body radiation therapy using the genomically adjusted radiation dose","volume":"13","author":"Ahmed","year":"2018","journal-title":"J Thorac Oncol"},{"key":"10.1016\/j.ctro.2023.100719_b0170","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1016\/j.jocn.2014.07.019","article-title":"Stereotactic radiosurgery for 318 brain metastases in a single Australian centre: the impact of histology and other factors","volume":"22","author":"Sia","year":"2015","journal-title":"J Clin Neurosci"},{"key":"10.1016\/j.ctro.2023.100719_b0175","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1007\/s11060-020-03691-6","article-title":"Local control and patterns of failure for \u201cRadioresistant\u201d spinal metastases following stereotactic body radiotherapy compared to a \u201cRadiosensitive\u201d reference","volume":"152","author":"Zeng","year":"2021","journal-title":"J Neurooncol"},{"key":"10.1016\/j.ctro.2023.100719_b0180","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1016\/j.adro.2017.07.011","article-title":"SBRT to adrenal metastases provides high local control with minimal toxicity","volume":"2","author":"Plichta","year":"2017","journal-title":"Adv Radiat Oncol"},{"key":"10.1016\/j.ctro.2023.100719_b0185","doi-asserted-by":"crossref","first-page":"624","DOI":"10.3109\/0284186X.2012.671957","article-title":"Serious gastric ulcer event after stereotactic body radiotherapy (SBRT) delivered with concomitant vinorelbine in a patient with left adrenal metastasis of lung cancer","volume":"51","author":"Onishi","year":"2012","journal-title":"Acta Oncol"},{"key":"10.1016\/j.ctro.2023.100719_b0190","article-title":"Stereotactic magnetic resonance-guided online adaptive radiotherapy of adrenal metastases combines high ablative doses with optimized sparing of organs at risk","volume":"39","author":"Hoegen","year":"2023","journal-title":"Clin Transl Radiat Oncol"},{"key":"10.1016\/j.ctro.2023.100719_b0195","doi-asserted-by":"crossref","first-page":"858","DOI":"10.1016\/j.ijrobp.2018.05.048","article-title":"MR-guided gated stereotactic radiation therapy delivery for lung, adrenal, and pancreatic tumors: A geometric analysis","volume":"102","author":"van Sornsen de Koste","year":"2018","journal-title":"Int J Radiat Oncol Biol Phys"}],"container-title":["Clinical and Translational Radiation Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2405630823001441?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2405630823001441?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,3,17]],"date-time":"2025-03-17T02:41:39Z","timestamp":1742179299000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2405630823001441"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,3]]},"references-count":39,"alternative-id":["S2405630823001441"],"URL":"https:\/\/doi.org\/10.1016\/j.ctro.2023.100719","relation":{},"ISSN":["2405-6308"],"issn-type":[{"type":"print","value":"2405-6308"}],"subject":[],"published":{"date-parts":[[2024,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Multi-institutional experience of MR-guided stereotactic body radiation therapy for adrenal gland metastases","name":"articletitle","label":"Article Title"},{"value":"Clinical and Translational Radiation Oncology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ctro.2023.100719","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 The Authors. Published by Elsevier B.V. on behalf of European Society for Radiotherapy and Oncology.","name":"copyright","label":"Copyright"}],"article-number":"100719"}}